Last reviewed · How we verify
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers
The purpose of this study is to assess the safety, reactogenicity, and immunogenicity of Ad26.ZIKV.001 at 2 dose levels, 5\*10\^10 viral particles (vp) and 1\*10\^11 vp, administered intramuscularly as single dose and as 2-dose schedules in healthy adults.
Details
| Lead sponsor | Janssen Vaccines & Prevention B.V. |
|---|---|
| Phase | PHASE1 |
| Status | COMPLETED |
| Enrolment | 100 |
| Start date | Sun Nov 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Mon Sep 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Healthy
Interventions
- Ad26.ZIKV.001 5*10^10 vp
- Ad26.ZIKV.001 1*10^11 vp
- Placebo
Countries
United States